EUCTR2018-004802-24-NLActive, not recruitingPhase 1
Optimizing timing of glucocorticoid treatment in children with congenitaladrenal hyperplasia - OPTIMED study
Radboud University Nijmegen Medical Centre0 sites50 target enrollmentStarted: May 13, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Children with CAH due to 21-hydroxylase deficiency > 4 years old and
- •< 18 years old
- •The diagnosis is confirmed by mutation analysis
- •Patient are treated with hydrocortisone according to standard
- •guidelines in a thrice daily schedule
- •Ability to collect saliva
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Other forms of CAH
- •Not able to collect saliva
- •Chronical medication use other than hydrocortisone and
- •fludrocortisone
Investigators
Similar Trials
Completed
Not Applicable
To study the effects of 2 standard treatment-timing strategies for glucocorticoïd dosage on androgen concentration in CAH childreCongenital adrenal hyperplasia (AGS)NL-OMON25245Radboudumc, Department of pediatric endocrinology50
Completed
Not Applicable
Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasiaCAHNL-OMON48168Radboud Universitair Medisch Centrum50
Completed
Not Applicable
Optimal regimens of glucocorticoids tapering for remission induction therapy in patients with severe systemic lupus erythematosus : multi-center randomized open label trialsystemic lupus erythematosusJPRN-UMIN000035865Juntendo University44
Not yet recruiting
Not Applicable
Evaluation of cumulative steroid doses in adult nephrotic syndromeCTRI/2021/04/033110Funding applied for
Recruiting
Phase 4
Optimal tapering regimens of glucocorticoid for severe SLE: multi-center randomized open label trialsystemic lupus erythematosusSLED008180JPRN-jRCT1031180196Tamura Naoto100